Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects. - CRS. Experts. Early Phase.

Single and Repeated Doses of EGb 761® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects.

Science

ShareTwitter FacebookXingLinkedin

drug-drug interaction EGb 761®Ginkgo biloba extract healthy subjects pharmacodynamics pharmacokinetics rivaroxaban

You May Also Like

Science 16. November 2023

Pharmacokinetics, Safety, and Tolerability of the Novel Tetrameric, High-Relaxivity, Macrocyclic Gadolinium-Based Contrast Agent Gadoquatrane in Healthy Adults

Science 16. November 2023

Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects

Science 25. Mai 2023

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes